Dual Protein Farnesyltransferase−Geranylgeranyltransferase-I Inhibitors as Potential Cancer Chemotherapeutic Agents
S. J. DESOLMS(Duke University), Jeffrey S. Taylor(United States Military Academy), Robert B. Lobell(United States Military Academy), Nancy E. Kohl(United States Military Academy), Samuel Graham(Georgia Institute of Technology), Kelly Hamilton(United States Military Academy), Nancy N. Tsou(Duke University), Eileen S. Walsh(Janssen (Switzerland)), L.S. Beese(Duke University), Carolyn A. Buser(United States Military Academy), Suzanne C. MacTough(Duke University), Terrence M. Ciccarone(Duke University), R. Robinson(United States Military Academy), Anthony W. Shaw(Duke University), Hans E. Huber(Health Strat (Kenya)), Christine Fernandes(United States Military Academy), Michelle Ellis-Hutchings(United States Military Academy)
Cited by 60
Related Papers
Ultrawide‐Bandgap Semiconductors: Research Opportunities and Challenges
|Advanced Electronic Materials|2017|1.5k
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
|Cancer Immunology Research|2015|440
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors
|Biochemical Journal|2005|396
Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage
|Cancer Cell|2005|271
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
|Proceedings of the National Academy of Sciences|1998|210